Digital Mobile Venture, an investment fund, led a $100m Series D round in Acepodia, a clinical stage biotechnology company. "This financing illustrates the confidence of Acepodia's current investors in our team, our mission, and our differentiated platform, and we are extremely grateful for their support. These funds will directly promote the progression of our clinical and pre-clinical candidates and also continue the validation of our ACC and allogeneic gamma delta 2 T-cell platforms to advance the development of innovative, effective, and importantly affordable off-the-shelf allogeneic cell therapies," Sonny Hsiao, Acepodia CEO.